Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-01-07 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关联交易决策制度
Governance Information Classification · 95% confidence The document is titled '关联交易决策制度' which translates to 'Related Party Transaction Decision System' and is issued by 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It details the policies, definitions, principles, decision-making procedures, and disclosure requirements for related party transactions according to Chinese securities laws and Shenzhen Stock Exchange and Hong Kong Stock Exchange listing rules. The content is regulatory and governance-focused, outlining internal rules and compliance procedures for related party transactions rather than reporting financial results or announcing events. It is a governance document describing the company's internal rules and governance practices related to related party transactions. Therefore, the document fits best under Governance Information (CGR). The document length (over 10,000 characters) and detailed procedural content confirm it is not a brief announcement or a report publication notice.
2021-01-07 Chinese
公司章程（草案）修订对照表
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for 贝达药业股份有限公司 (Betta Pharmaceuticals Co. Ltd.). It includes extensive provisions on company organization, shareholder rights, share issuance, share transfer, capital structure, and governance rules. The text references Chinese company law, securities law, and specific regulatory requirements for companies listed in Shenzhen and Hong Kong. It also includes detailed rules on share repurchase, share transfer restrictions, and board responsibilities. This type of document is a governance document that outlines the internal rules and structure of the company rather than a financial report, announcement, or other filing type. Therefore, the most appropriate classification is Governance Information (CGR).
2021-01-07 Chinese
监事会议事规则
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules'. It details the rules and procedures for the supervisory board meetings of the company, including the composition, responsibilities, meeting convocations, voting procedures, record keeping, and other governance-related matters. It references relevant laws and listing rules but does not contain financial statements, audit results, or any financial performance data. It is a governance document outlining internal rules and procedures for the supervisory board, which fits the definition of Governance Information (CGR). The document length is about 4500 characters, which is sufficient for a detailed governance report rather than a brief announcement or notice. Therefore, the appropriate classification is Governance Information (CGR).
2021-01-07 Chinese
独立董事关于第三届董事会第十四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a specific agenda item for the company's 14th board meeting of the third session. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange rules, indicating compliance and governance matters. The content focuses on pre-approval and opinions related to anticipated related-party transactions, emphasizing fairness and protection of shareholder interests. There are no financial statements, earnings data, or report attachments. The document is a governance-related statement about board meeting matters, not a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial data or detailed report content, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing (RNS) because it is a formal opinion rather than a certification or miscellaneous announcement.
2021-01-07 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Betta Pharmaceuticals Co., Ltd. It contains detailed chapters on company organization, share issuance, shareholder meetings, board of directors, management, financial accounting, share transfer, and other governance-related provisions. It references Chinese company law, securities law, and Hong Kong listing rules, indicating it is a formal governance document. The content is not a financial report, earnings release, or announcement but a comprehensive governance charter. Therefore, it fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not a brief announcement or summary.
2021-01-07 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and is issued by 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It is a detailed internal policy document outlining the principles, approval authorities, organizational structure, management, financial management, auditing, and disclosure obligations related to the company's external investments. The document references relevant laws and stock exchange listing rules (Shenzhen Stock Exchange, Hong Kong Stock Exchange) and describes internal procedures and controls for investment activities. It does not contain financial statements, earnings data, or audit opinions, nor is it a report or announcement of financial results or corporate governance changes. It is a governance-related internal policy document focused on investment management practices and compliance. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7891 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive governance policy document.
2021-01-07 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.